

# Tilray Expands Pharmacy Access to Medical Cannabis in Germany

## Tilray Medical Expands Presence in Germany With New Good Supply Strains

### *Strengthening Commitment to German Health Care*

Tilray Medical, the medical division of Tilray Brands Inc., announced on August 28 the launch of three new EU-GMP certified cannabis strains in Germany. The move reinforces the company's position as a leading global medical cannabis supplier and expands access for patients and pharmacies under Germany's established medical framework.

The new offerings Good Supply Cannabisblüten THC 22 IIM, THC 25 MMK, and THC 18 LLD will be available in both 15-gram jars for patients and 500-gram packs for pharmacies, providing flexibility to meet diverse prescribing and dispensing needs. Tilray Medical emphasized that the products are designed to align with Germany's rigorous quality standards while ensuring accessibility for patients requiring cannabis-based therapies.

### **A Trusted Partner for Patients and Physicians**

In a statement, Rajnish Ohri, managing director of international operations for Tilray Brands, underscored the company's global vision for medical cannabis. He noted that Tilray's mission is to strengthen the therapeutic alliance between patients and health care practitioners by offering consistent, high-quality options supported by a robust distribution network.

"By introducing these new Good Supply strains to the German market, we are expanding access to premium, EU-GMP certified options for physicians and patients," Ohri said. "This reaffirms our role as a trusted partner in medical cannabis across continents."

### **Launch Timeline for New Strains**

The rollout of Tilray's new Good Supply products in Germany will take place in stages this fall:

- **Good Supply Cannabisblüten THC 22 IIM** – available at the beginning of September.
- **Good Supply Cannabisblüten THC 25 MMK** – launching September 19.

- **Good Supply Cannabisblüten THC 18 LLD** – expected by late September or early October.

This phased introduction allows pharmacies to adjust inventories and ensures steady supply as patient demand grows.

## **Expanding Good Supply Into Europe**

Good Supply is one of Canada's most recognized cannabis brands, known for its reliable quality and accessible product formats. Tilray Medical has adapted these strains to meet the strict EU-GMP requirements necessary for the German market, which continues to be one of Europe's largest destinations for medical cannabis.

Under Germany's program, medical cannabis is dispensed by prescription through pharmacies. Tilray's well-established logistics and distribution platform in Neumünster ensures that pharmacies receive consistent and reliable deliveries, a factor that has been critical for maintaining physician and patient trust.

## **Tilray's Broader Strategy in Global Medical Cannabis**

The launch of these strains is part of Tilray's broader strategy to solidify its leadership in international medical cannabis markets. Germany has long been considered a cornerstone for European cannabis, both due to its size and its structured regulatory framework.

By introducing new Good Supply options, Tilray Medical is signaling its intent to continue scaling within the European Union, leveraging its experience from established North American operations. The company's expansion reflects not only the growing demand for medical cannabis but also a broader trend toward harmonized standards and patient access in Europe.

## **Looking Ahead**

With these new introductions, Tilray Medical continues to position itself as a central player in Germany's evolving medical cannabis landscape. As physicians and patients gain more choices, and as pharmacies benefit from streamlined distribution, Tilray is betting that its combination of global reach, compliance with strict EU standards, and brand recognition will solidify its leadership.

The company's commitment to innovation and accessibility underscores the increasing integration of cannabis into mainstream health care, a shift that Germany, with its structured medical program, is helping to lead in Europe.

Email: [info@cannabisriskmanager.com](mailto:info@cannabisriskmanager.com) | Phone: +415-226-4060

© Copyright 2025 Cannabis Risk Manager. All Rights Reserved